GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » Cash Ratio

Cutia Therapeutics (HKSE:02487) Cash Ratio : 10.65 (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Cutia Therapeutics Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Cutia Therapeutics's Cash Ratio for the quarter that ended in Jun. 2023 was 10.65.

Cutia Therapeutics has a Cash Ratio of 10.65. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Cutia Therapeutics's Cash Ratio or its related term are showing as below:

HKSE:02487' s Cash Ratio Range Over the Past 10 Years
Min: 4.99   Med: 13.91   Max: 71.6
Current: 4.99

During the past 3 years, Cutia Therapeutics's highest Cash Ratio was 71.60. The lowest was 4.99. And the median was 13.91.

HKSE:02487's Cash Ratio is ranked better than
64.5% of 1507 companies
in the Biotechnology industry
Industry Median: 2.95 vs HKSE:02487: 4.99

Cutia Therapeutics Cash Ratio Historical Data

The historical data trend for Cutia Therapeutics's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutia Therapeutics Cash Ratio Chart

Cutia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Cash Ratio
71.60 13.91 4.99

Cutia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Cash Ratio 71.60 - 13.91 10.65 4.99

Competitive Comparison of Cutia Therapeutics's Cash Ratio

For the Biotechnology subindustry, Cutia Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cutia Therapeutics's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Cutia Therapeutics's Cash Ratio falls into.



Cutia Therapeutics Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Cutia Therapeutics's Cash Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash Ratio (A: Dec. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=1202.151/86.436
=13.91

Cutia Therapeutics's Cash Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash Ratio (Q: Jun. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=1530.145/143.666
=10.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cutia Therapeutics  (HKSE:02487) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Cutia Therapeutics Cash Ratio Related Terms

Thank you for viewing the detailed overview of Cutia Therapeutics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cutia Therapeutics (HKSE:02487) Business Description

Traded in Other Exchanges
N/A
Address
436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070
Cutia Therapeutics is a dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases.
Executives
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Fil Limited 2201 Interest of corporation controlled by you
Shen Nan Peng 2201 Interest of corporation controlled by you
Snp China Enterprises Limited 2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund V, L.p. 2201 Interest of corporation controlled by you
Hsg Growth V Holdco Q, Ltd 2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p. 2201 Interest of corporation controlled by you
Hsg Holding Limited 2201 Interest of corporation controlled by you
Ma Yun 2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Aurora Cutis Limited 2301 Trustee

Cutia Therapeutics (HKSE:02487) Headlines

No Headlines